AC Immune Refines Pipeline Strategy and Enhances Operational Efficiency to Extend Cash Reserves
Written by Emily J. Thompson, Senior Investment Analyst
Source: Newsfilter
Updated: Sep 04 20250mins
Strategic Focus and Workforce Reduction: AC Immune is sharpening its focus on late-stage clinical development for Alzheimer's and Parkinson's diseases, resulting in a 30% workforce reduction to enhance operational efficiencies.
Extended Cash Runway: The company has extended its cash resources to support operations until the end of Q3 2027, with CHF 127.1 million available as of June 30, 2025, excluding potential partnership payments.
ACIU.O
$0.0000%Past 6 months
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
No Data
Powered By
Intellectia
Analyst Views on ACIU
Wall Street analysts forecast ACIU stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ACIU is 10.00 USD with a low forecast of 8.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 3.220
Low
8.00
Averages
10.00
High
12.00
Current: 3.220
Low
8.00
Averages
10.00
High
12.00
HC Wainwright & Co.
Andrew Fein
Strong Buy
Reiterates
$16
2025-04-03
Reason
HC Wainwright & Co.
Andrew Fein
Price Target
$16
2025-04-03
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Andrew Fein
Strong Buy
Reiterates
$16
2025-03-14
Reason
HC Wainwright & Co.
Andrew Fein
Price Target
$16
2025-03-14
Reiterates
Strong Buy
Reason
See All Ratings
About ACIU
AC Immune SA is a Switzerland-based clinical-stage biopharmaceutical company. The Company focuses on precision medicine for neurodegenerative diseases. It designs, discovers and develops therapeutic, as well as diagnostic products for prevention, diagnosis and treatment of diseases caused by misfolding proteins. Its SupraAntigen and Morphomer technology platforms to create antibodies, small molecules and vaccines designed to address a broad range of neurodegenerative indications, such as Alzheimer's disease (AD). The Company's pipeline includes nine therapeutic product candidates with five in clinical trials, and three diagnostic candidates. Its lead product candidate is Crenezumab, a humanized and monoclonal anti-Abeta antibody for Alzheimer’s disease. It has collaborations with pharmaceutical companies, including Roche/Genentech, Eli Lilly, Biogen, Janssen Pharmaceuticals, Nestle Institute of Health Sciences, Life Molecular Imaging (formerly Piramal Imaging) and Essex Bio-Technology.
About the author
Preview
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sigh Up to Get Intellectia Insights
How did the company's recent strategic decisions impact its latest financial performance?
Can you explain the factors behind the recent changes in the company's stock price?
What are the expected impacts of current market trends on the company's future growth?
Based on the latest earnings report, what are the company's forecasted revenues for the next quarter?